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Abstract
The fluoropyrimidines 5-fluorouracil (5-FU) and FdUrd (5-fluorodeoxyuridine; floxuridine) are the backbone of
chemotherapy regimens for colon cancer and other tumors. Despite their widespread use, it remains unclear how these
agents kill tumor cells. Here, we have analyzed the checkpoint and DNA repair pathways that affect colon tumor responses
to 5-FU and FdUrd. These studies demonstrate that both FdUrd and 5-FU activate the ATR and ATM checkpoint signaling
pathways, indicating that they cause genotoxic damage. Notably, however, depletion of ATM or ATR does not sensitize
colon cancer cells to 5-FU, whereas these checkpoint pathways promote the survival of cells treated with FdUrd, suggesting
that FdUrd exerts cytotoxicity by disrupting DNA replication and/or inducing DNA damage, whereas 5-FU does not. We also
found that disabling the base excision (BER) repair pathway by depleting XRCC1 or APE1 sensitized colon cancer cells to
FdUrd but not 5-FU. Consistent with a role for the BER pathway, we show that small molecule poly(ADP-ribose) polymerase
1/2 (PARP) inhibitors, AZD2281 and ABT-888, remarkably sensitized both mismatch repair (MMR)-proficient and -deficient
colon cancer cell lines to FdUrd but not to 5-FU. Taken together, these studies demonstrate that the roles of genotoxin-
induced checkpoint signaling and DNA repair differ significantly for these agents and also suggest a novel approach to
colon cancer therapy in which FdUrd is combined with a small molecule PARP inhibitor.
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Introduction
5-fluorouracil has activity in multiple cancers and is one of the
most widely prescribed anticancer agents, but its most frequent use
is in colon cancer, where it is the basis for all modern colon cancer
therapies. After uptake into cells, 5-FU undergoes complex
metabolic reactions (Fig. 1A; rev. in [1]) to produce 3 known
cytotoxic metabolites: FUTP (5-fluorouridine triphosphate),
FdUMP (5-deoxyuridine monophosphate), and FdUTP (5-deox-
yuridine triphosphate). The FUTP affects RNA metabolism
following its incorporation into cellular RNA, where it disrupts
snRNA, tRNA, and rRNA processing as well as the ribonucleolytic
activity of the exosome and pseudouridylation of RNA [2–8].
In contrast, FdUMP and FdUTP disrupt DNA metabolism.
These metabolites areproduced followingthe conversion of 5-FU to
FdUrd (5-fluorodeoxyuridine; floxuridine), which is also an FDA-
approved chemotherapy agent for the treatment of colon cancer [9]
and is often considered to have a similar mechanism of action as 5-
FU. FdUrd is then phosphorylated to FdUMP and further
phosphorylated to FdUTP [1]. The FdUMP inhibits thymidylate
synthase (TS), which prevents the conversion of dUMP to dTMP,
ultimately causing the depletion of dTTP, the accumulation of
dUTP, and the disruption of dNTP ratios. In contrast, FdUTP, as
well as the accumulated dUTP, are incorporated into DNA.
Consistent with their abilities to disrupt dNTP levels, both
FdUrd and 5-FU activate the ATR checkpoint signaling pathway
[10–17], a pathway that is triggered when DNA replication is
inhibited and that also plays critical roles in promoting survival of
cells experiencing replication stress produced by dNTP disruption
and/or DNA lesions [18]. Once activated, ATR phosphorylates
multiple substrates, including Chk1. The collective kinase activities
of ATR and Chk1 orchestrate the S phase checkpoint and regulate
DNA repair to promote cell viability and recovery [19].
Additionally, 5-FU and FdUrd also cause double strand DNA
breaks [20,21], which in turn activate the ATM checkpoint
signaling pathway. The ATM pathway also regulates cell survival
by either inducing apoptosis or preventing cell cycle progression
and activating DNA repair, both of which promote survival [22].
Notably, however, it remains unclear whether the ATR and/or
ATM checkpoint pathways play important roles in determining
the survival of human colon cancer cells, the cells that are targeted
by 5-FU and FdUrd in patients, when they are treated with these
agents.
The uracil and 5-FU that are incorporated into the genome are
also recognized by 2 DNA repair pathways that may play roles in
the survival of cells treated with 5-FU and FdUrd. One pathway is
the base excision repair (BER) pathway [1,23]. In this pathway,
genomically incorporated uracil and 5-FU are first recognized by
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The abasic site is further processed by an endonuclease (e.g.,
APE1), creating a single-stranded DNA break that is recognized by
poly(ADP-ribose) polymerase, which poly(ADPribosyl)ates itself as
well as other repair proteins, recruiting XRCC1 and other
proteins that complete repair [24]. Investigations into the role of
BER in cells treated with 5-FU or FdUrd have reached disparate
conclusions using a wide variety of model systems. Given that
these studies have shown that disabling BER protects, sensitizes, or
has no effect on the cytotoxicity induced by 5-FU and FdUrd in
these varied systems, including mouse [17,23,25–35], it remains
unclear what, if any, role BER plays in the survival of colon cancer
cells exposed to 5-FU or FdUrd.
The other implicated repair pathway is the mismatch repair
(MMR) system. In vitro studies have found that the MMR pathway
can remove 5-FU from artificial substrates containing 5-FU:G
mispairs. Notably, however, studies in cells suggest that MMR
plays only a minor role in the excision of 5-FU lesions in the
genome [35]. Analyses of the effects of the MMR pathway on cell
viability following treatment with 5-FU and FdUrd have generally
indicated that cells with defective MMR are more resistant to 5-
FU and FdUrd [10,36–38], a result consistent with the finding that
MMR-defective colon cancer patients do not benefit from 5-FU
therapy [39].
Given the multiple mechanisms of action of 5-FU and FdUrd
and the wide range of experimental systems used in these studies
(including studies in mouse cell lines and in human cell lines
derived from tumors that are not typically treated with 5-FU or
FdUrd), we have initiated studies to address the roles of individual
checkpoint signaling and DNA repair pathways in human cells
derived from human tumors. In our first analysis, we found that 5-
FU and FdUrd have very different mechanisms of action in
ovarian cancer cells [17]. Disabling ATR or BER sensitized these
cells to FdUrd, but not 5-FU, indicating that FdUrd kills cells by
causing DNA damage and that 5-FU exerts its cytotoxicity by
another mechanism, possibly by disrupting RNA metabolism.
Notably, we also found that PARP inhibitors, which have shown
unprecedented activity against ovarian tumors and other tumors
that have mutated BRCA1 and BRCA2 [40–43], remarkably
sensitized ovarian cancer cells to FdUrd but not 5-FU [17]. Given
that FdUrd is active in ovarian cancer [44,45], that defects in
BRCA1 and BRCA2 (or other genes in the homologous repair
pathway) are common in ovarian cancer [46], and that PARP
inhibitors will likely have a role in the treatment of ovarian cancers
[24], these findings suggested a novel therapeutic strategy in
ovarian cancer. Notably, however, the biology of ovarian cancer is
very different from the biology of colon cancer. The oncogenes
and tumor suppressor genes commonly mutated in colon cancers
(APC, p53, PI3K, KRAS) differ from the genes commonly mutated
in ovarian cancers (NF1, RB1, CDK12, CCNE1, NOTCH) [46,47].
Furthermore, the DNA repair pathways that are disrupted in
colon cancer cells are vastly different from those disrupted in
Figure 1. 5-FU and FdUrd activate the ATR and ATM checkpoint signaling pathways. (A) Metabolism of 5-FU and FdUrd. (B, C) HT29 (B)
and HCT-8 (C) cells were treated with 5-FU (80 mM, HT29 cells; 200 mM HCT-8 cells), FdUrd (40 mM for both cell lines), or 10 mM hydroxyurea (HU) for
the indicated times. Cell extracts were blotted for phospho-Ser317-Chk1 (P-Chk1), phospho-Thr68-Chk2 (P-Chk2), Chk1, or Chk2. TS, thymidylate
synthase; TP, thymidine phosphorylase; UP, uridine phosphorylase; UK, uridine kinase; OPRT, orotate phosphoribosyltransferase; RR, ribonucleotide
reductase; FUR, 5-fluorouridine; FUMP, 5-fluorouridine monophosphate; FUDP, 5-fluorouridine diphosphate; FUTP, 5-fluorouridine triphosphate;
FdUMP, 5-fluorodeoxyuridine monophosphate; FdUDP, 5-fluorodeoxyuridine diphosphate; FdUTP, 5-fluorodeoxyuridine triphosphate.
doi:10.1371/journal.pone.0028862.g001
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repair pathway (e.g., MLH1 and MSH2) are often mutated or
epigenetically silenced in colon cancers [39,48], whereas defects in
homologous recombination (e.g., BRCA1 and BRCA2 mutations)
occur in ovarian cancers [46,47]. Finally, ovarian and colon
tumors have very different responses to 5-FU. Whereas 5-FU has
very limited activity in ovarian cancer [49,50], 5-FU is the
cornerstone for all chemotherapy regimens used to treat colon
cancers due to its high activity in this disease [1]. Therefore, given
these biological differences between ovarian and colon cancers,
and the fact that 5-FU is universally used in colon cancer
chemotherapy regimens, we have now determined how 5-FU and
FdUrd kill colon cancer cells to gain important insights underlying
the biology of these agents and improve their use in the clinic to
treat this disease. To that end, we initiated a systematic analysis of
the roles of genotoxin-activated checkpoint signaling, the BER
pathway, and the MMR pathway by depleting key signaling
intermediates in these pathways using highly effective siRNAs.
These findings not only further illuminate our understanding of
the signaling and DNA repair pathways that are important in
these cells, they also reveal that colon tumor cells are sensitized to
FdUrd by small molecule PARP inhibitors that are currently in
clinical trials, thus suggesting a novel therapeutic approach that
combines FdUrd, a drug approved for the treatment of colon
cancer, with a PARP inhibitor, an emerging class of agents with
exciting anticancer activity.
Materials and Methods
Cell lines and culture
HT29, HCT-8, and HCT-116 cells were obtained from
American Type Culture Collection. HCT-116.ch2 and HCT-
116.ch3 [51] cells were from Scott Kaufmann (Mayo Clinic). Cells
were cultured in RPMI-1640 media (Mediatech) supplemented
with 10% fetal bovine serum (Atlanta Biologicals) at 37uCi n5 %
CO2. For clonogenic assays, the medium was supplemented with
100 U/mL penicillin and 100 mg/mL streptomycin (Mediatech).
Materials
Reagents were from the following suppliers: 5-fluorouracil (APP
Pharmaceuticals), FdUrd (Bedford Laboratories), ABT-888 (Sell-
eck Chemicals and ChemieTek), AZD2281 (ChemieTek), KU-
55933 (Tocris Bioscience), gemcitabine (Eli Lilly), SuperSignal
Pico West (Thermo Scientific). All other materials were from
Sigma-Aldrich.
Antibodies were as follows: phospho-Ser317-Chk1 (R&D
Systems); phospho-Thr68-Chk2, ATR, horseradish peroxidase-
linked rabbit IgG, and horseradish peroxidase-linked mouse IgG
(Cell Signaling); Chk1 (Santa Cruz Biotechnology); Chk2 and
ATM (Epitomics); APE1 (Abcam); XRCC1 (Bethyl Laboratories);
beta-actin (Sigma-Aldrich); and HSP90, D. Toft (Mayo Clinic,
Rochester, MN).
Cell transfections and small interfering (si)RNAs
siRNAs were transfected by electroporation as described [17].
The transfected cells were cultured for 48 h before use. Sequences
of siRNAs were: ATM-1, 59-GCACCAGUCCAGUAUUGGC-39
[52]; ATR-2, 59-CCUCCGUGAUGUUGCUUGA-39 [53];
XRCC1-2, 59-CUCGACUCACUGUGCAGAA-39 [54]; APE1,
59-GGACAGAGCCAGAGGCCAA-39; MLH1, 59-GGAAGAU-
UCUGAUGUGGAA-39; MSH2, 59-GAUCCUAAUCUCAGU-
GAAU-39; and luciferase, 59-CUUACGCUGAGUACUUCGA-
39 [55].
Clonogenic assays, cell lysis, and cell irradiation
Cell cycle analyses, clonogenic assays, cell lysis, immunoblotting
and immunostaining were performed as described [56,57]. For
clonogenic assays using non-transfected cells, percent survivals of
all individual and combination treatments were normalized to cells
treated with vehicle only. For clonogenic assays using cells
transfected with siRNA, percent survivals at each drug concen-
tration were normalized to the vehicle-treated control for the given
siRNA. Cells were irradiated with a RS-2000 Biological Irradiator,
Rad Source (Suwanee, GA) 4–6 h after plating.
Results
5-FU and FdUrd activate the ATR and ATM checkpoint
signaling pathways in colon cancer cells
To assess the effects of 5-FU and FdUrd on the ATM and ATR
checkpoint signaling pathways, we compared the abilities of these
agents to activatecheckpointsignalingin two colon cancer cell lines:
HT29, which have a functional MMR system, and HCT-8, which
have a mutations in MSH6 and are MMR deficient [58]. Cells were
treated with concentrations of each agent that inhibit clonogenicity
by 90% (IC90) and, as a positive control, the replication inhibitor
hydroxyurea. Activation of the ATM and ATR pathways was then
assessed by immunoblotting for phosphorylated Chk1 and Chk2,
two protein kinases that are phosphorylated and activated by ATR
and ATM [59]. These studies revealed that 5-FU and FdUrd
strongly activated Chk1 and Chk2 in HT29 cells (Fig. 1B), with 5-
FU causing even greater levels of Chk1 phosphorylation than did
FdUrd. Similarly, in HCT-8 cells, both agents induced Chk1
phosphorylation (Fig. 1C); however, in these cells 5-FU induced less
Chk1 than did FdUrd. Analyses of Chk2 phosphorylation were not
possible due to the very low levels of Chk2 in the HCT-8 cells (data
not shown). Taken together, these results demonstrate that both
agents cause genotoxic damage that activates checkpoint signaling
pathways in colon cancer cells.
ATR and ATM promote the survival of colon cancer cells
treated with FdUrd but not 5-FU
ATM and ATR are the two apical kinase regulators of
genotoxin-induced checkpoint signaling. To determine if either
ATM or ATR activate pathways that affect the survival of cells
treated with FdUrd or 5-FU, we transiently depleted ATM and
ATR using siRNAs, and then assessed the capacity of cells treated
with graded concentrations of FdUrd or 5-FU to proliferate using
clonogenic assays. Surprisingly, depletion of ATM or ATR did not
sensitize either cell line to 5-FU (Fig. 2A and 2B), even though this
agent activated these pathways (see Fig. 1B and 1C). A far different
picture emerged when the cells were treated with FdUrd.
Depletion of ATR dramatically sensitized HT29 cells to FdUrd
(Fig. 2B) and to gemcitabine (Fig. S1A), a nucleoside analog that
inhibits ribonucleotide reductase and disrupts DNA replication
when incorporated into DNA [60]. In contrast, ATM depletion
(Fig. 2A) and the ATM inhibitor KU-55933 [61] (Fig. S1C), both
of which sensitized to ionizing radiation (Fig. S1B and Fig S1D),
had minimal effects on FdUrd cytotoxicity. Similar results were
also seen in HCT-8 and HCT-116 cells, in which ATR depletion
sensitized both cell lines to FdUrd but not 5-FU (Fig. 3).
Disruption of BER by depleting XRCC1 sensitizes to
FdUrd but not 5-FU
5-FU and FdUrd cause the accumulation of uracil and 5-
fluorouracil in genomic DNA [23,62]. Studies using purified uracil
glycosylases have shown that synthetic substrates bearing uracil
PARP Inhibitors Sensitize to Floxuridine
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machinery [35,63–70]. Furthermore, a recent report demonstrat-
ed that in intact cells, uracil glycosylases remove 5-FU from the
genomes of colon cancer cells exposed to FdUrd [35]; notably,
however, in these studies, depletion of the glycosylases did not
affect the sensitivity to FdUrd. Therefore, to examine whether
disabling BER affected the sensitivity of HT29 cells to FdUrd, we
used siRNAs to deplete XRCC1 and APE1, two downstream key
participants in the BER pathway, and examined their sensitivity to
FdUrd. Significantly, depletion of XRCC1 (Fig. 4) and APE1 (Fig.
S2) sensitized cells to FdUrd. In contrast, XRCC1 depletion did
not sensitize these cells to 5-FU (Fig. 4), thus indicating that BER
does not play a role in promoting the survival of cells treated with
5-FU and further suggesting that 5-FU exerts its cytotoxic effects
independently of DNA replication or damage.
Small molecule PARP inhibitors sensitize colon cancer
cells to FdUrd but not 5-FU
Given that XRCC1 and APE1 depletion sensitized colon cancer
cells to FdUrd, and that PARP plays a key role in BER, we
reasoned that PARP inhibitors may sensitize colon cancer cells to
FdUrd. We therefore exposed HCT-8 and HT29 cells to graded
concentrations of FdUrd or 5-FU along with 3 mM ABT-888
(veliparib [71]), a concentration that was reported previously to
sensitize multiple tumor cell lines to a variety of chemotherapy
agents [17,72]. As shown in Fig. 5, ABT-888 robustly sensitized
HCT-8 and HT29 cells to FdUrd, whereas ABT-888 did not alter
the antiproliferative effects of 5-FU. To further demonstrate that
PARP inhibitors sensitize these cells to FdUrd, we also tested the
PARP inhibitor AZD2281 (olaparib [73]), which has shown
unprecedented activity in heavily pretreated patients with
BRCA1- and BRCA2-deficient tumors [40–43]. Similar to the
results seen with ABT-888, AZD2281 robustly sensitized both cell
lines to FdUrd (Fig. 5), further supporting the idea that PARP
inhibition sensitizes colon tumor cells to FdUrd.
Small molecule PARP inhibitor sensitization to FdUrd is
independent of MMR status
Previous reports demonstrated that cells with defects in MMR
are more resistant to FdUrd [10,36–38]. Similarly, patients treated
with 5-FU do not benefit from 5-FU-based chemotherapies [39],
suggesting that an intact MMR pathway promotes killing by 5-FU.
Figure 2. Depletion of ATR sensitizes to FdUrd but not 5-FU, whereas ATM depletion does not affect sensitivity to either agent. (A,
B) HT29 cells, transfected with control (Luc), ATM (A), or ATR (B) siRNAs, were plated as single cells, exposed to the indicated concentrations of 5-FU or
FdUrd for 24 h, washed, cultured for 10 d, and stained with Coomassie Blue. Transfected cells were also sequentially immunoblotted (insets) to
detect ATM, ATR, and HSP90 (as a loading control). *, non-specific band.
doi:10.1371/journal.pone.0028862.g002
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potential therapeutic strategy, we reasoned that it would be
important to determine whether tumor cells with defects in MMR,
which occur in 15–20% of colon cancers [39], were sensitized to
FdUrd by a PARP inhibitor. To assess how MMR status affects
the sensitivity of colon cancer cells to FdUrd alone and to the
combination of FdUrd plus AZD2281 we used two model systems.
For the first model system, we used siRNAs to deplete MSH2 and
MLH1. Both siRNAs were highly effective, causing near-complete
loss of MLH1 and MSH2 (Fig. 6A) and disrupting MNNG (N-
methyl-n9-nitro-n-nitrosoguanidine)-induced G2/M arrest (Fig.
S3), which requires a functional MMR pathway [51]. Notably,
Figure 3. ATR depletion sensitizes HCT-8 and HCT-116 to FdUrd but not 5-FU. (A, B) HCT-8 (A) or HCT-116 (B) cells transfected with control
(Luc) or ATR siRNAs were plated as single cells, exposed to the indicated concentrations of 5-FU or FdUrd for 24 h, washed, cultured for 10 d, and
stained with Coomassie Blue. Transfected cells were also sequentially immunoblotted for ATR and HSP90 (a loading control). *, non-specific band.
doi:10.1371/journal.pone.0028862.g003
Figure 4. The BER pathway protects cells from FdUrd but not 5-FU. HT29 cells transfected with control (Luc) or XRCC1 siRNA were plated as
single cells, exposed to the indicated concentrations of 5-FU or FdUrd for 24 h, washed, cultured for 10 d, and stained with Coomassie Blue.
Transfected cells were also sequentially immunoblotted for XRCC1 and beta-actin (a loading control).
doi:10.1371/journal.pone.0028862.g004
PARP Inhibitors Sensitize to Floxuridine
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to FdUrd by AZD2281, and were modestly resistant to FdUrd
alone.
For the second model system, we employed the paired colon
cells lines, HCT-116.ch2 and HCT-116.ch3 [51]. These cell lines
were derived from parental HCT-116 cells, which have biallelic
inactivating MLH1 mutations that render them MMR-deficient
[74]. The HCT-116.ch3 cells contain an additional chromosome
3, which encodes a functional MLH1 that restores MMR. The
HCT-116.ch2 cells, which are used as a control, contain an
additional chromosome 2 and like the parental cells are MMR-
deficient. Consistent with previously published results, the MMR
deficient HCT-116.ch2 cells were modestly more resistant to
FdUrd than were the HCT-116.ch3 cells (Fig. 6B), which are
MMR proficient [75]. Notably, however, AZD2281 robustly
sensitized both cell lines to FdUrd. Taken together, these results
demonstrate that colon cancer cells with defects in the MMR
pathway can also be sensitized to FdUrd by a small molecule
PARP inhibitor.
Discussion
5-FU is among the most widely used anticancer chemotherapy
agents, and it (or the 5-FU prodrug capecitabine) is the backbone
Figure 5. Small molecule PARP inhibitors sensitize HCT-8 and HT29 cells to FdUrd but not 5-FU. HCT-8 or HT29 cells were plated as
single cells, exposed to the indicated concentrations of 5-FU or FdUrd along with 3 mM ABT-888, 300 nM AZD2281, or vehicle for 24 h. Following
washing, 3 mM ABT-888 or 300 nM AZD2281 were re-added, and the cells were cultured for 10 d and stained with Coomassie Blue.
doi:10.1371/journal.pone.0028862.g005
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third leading cause of cancer-related death in the United States
[76]. Despite its widespread use in the treatment of colon cancer, it
remains unclear how this agent kills colon tumor cells. Similarly,
FdUrd, which is often considered to have a similar mechanism of
action to 5-FU, is also used to treat colon tumors that have
metastasized to the liver. To gain insight into how these agents
affect colon cancer cells we first carried out comprehensive
analyses of the roles of the ATM and ATR checkpoint signaling
pathways in colon cancer cells exposed to 5-FU and FdUrd, and
then analyzed the role of the BER pathway, a repair pathway that
removes uracil and uracil analogs that are incorporated into the
genome. We previously compared the mechanisms by which 5-FU
and FdUrd kill ovarian cancer cells. Notably, however, 5-FU has
very limited clinical activity against ovarian cancer [49,50], and
the DNA repair pathways that are disrupted in ovarian cancer
differ from those disrupted in colon cancer. Specifically, ovarian
cancers frequently exhibit ‘‘BRCAness’’ due to defects in BRCA1
or BRCA2, or other ill-defined changes that disrupt the
homologous recombination DNA repair pathway [46]. In
contrast, in colon cancers the mismatch repair pathway is
frequently mutated or silenced [39,48], and the MMR pathway
has been reported to affect cell killing by 5-FU and FdUrd [36–
38,77,78]. Therefore, in the present report, we have performed
head-to-head comparison of these agents in MMR-proficient and -
deficient colon cancer cells that have been depleted of key
checkpoint signaling and BER pathway intermediates. Important-
ly, these mechanistic studies have uncovered novel insights into
how these agents kill colon cancer cells and identified a potential
therapeutic strategy against colon cancer.
First, our studies demonstrated the ATR—but not the ATM—
checkpoint signaling pathway plays a critical role facilitating the
survival of cells treated with FdUrd. Although previous studies
documented that FdUrd activates the ATM- and ATR-dependent
checkpoints [10,13,79], these studies did not compare the effects of
ATM and ATR depletions on the survival of tumor cells exposed
to both agents. Here we have addressed that question. Surpris-
ingly, we found that even though FdUrd has been reported to
cause double-stranded DNA breaks [20,21], ATM has only a
minor role in FdUrd-induced killing. In contrast, ATR depletion
severely sensitized to FdUrd, demonstrating that ATR plays a
critical role in stabilizing stalled replication forks and preventing
their collapse, thus promoting cell survival when cells are treated
with replication inhibitors such as the nucleoside analog
gemcitabine [60]. Therefore, the present studies suggest that the
disruption of DNA replication that occurs when TS is inhibited
and the subsequent disruption of dNTP levels is likely a major
mechanism by which FdUrd causes cytotoxicity.
Second, the present results help clarify the role of BER in colon
cancer cells exposed to 5-FU and FdUrd. Previous studies
examining the role of the BER pathway have found disparate
results, with increased, decreased, or unaltered sensitivity to 5-FU
or FdUrd in a variety of experimental systems [17,23,25–35]. In
contrast, the present results show that XRCC1 depletion sensitizes
to FdUrd but not 5-FU. This finding, along with our published
studies showing that an intact BER pathway protects ovarian
cancer cells treated with FdUrd [17], indicates that FdUrd inflicts
lesions that are cytotoxic to some human cancer cells. Consistent
with these findings, two potent and highly specific small molecule
inhibitors of PARP also sensitized to FdUrd. These results are
similar to what was observed in ovarian cancer cells [17].
However, given that ovarian cancer cells often exhibit BRCAness
(due to defects in homologous recombination) [46,80], a
phenotype that renders cells exquisitely sensitive to PARP
inhibitors [81], it remained an unanswered question whether
PARP inhibitors would also sensitize to FdUrd in colon cancer
cells, which do not have defects in homologous recombination. It
should be noted, however, that although our XRCC1 findings
strongly support a protective role for BER, the effects of the PARP
inhibitors may be more complicated. PARP not only plays an
important role in BER but also participates in other DNA repair
pathways and cell signaling pathways, raising the possibility that
the tremendous sensitization seen with the PARP inhibitors may
stem from effects on BER as well as other cellular pathways.
Third, the present studies show that depleting the apical
regulators of checkpoint signaling (ATR and ATM) or disabling
key BER pathway members (with XRCC1 and APE1 siRNAs or
PARP inhibitors) did not sensitize to 5-FU. Such results strongly
suggest that 5-FU is exerting its cytotoxic effects independently of
its effects on DNA replication or integrity. Notably, this result is
consistent with a number of studies showing that 5-FU mediates
cell killing by incorporating into RNA and interfering with RNA
metabolism [82–89]. In contrast, the finding that disabling the
ATR and BER pathways strongly sensitizes to FdUrd, indicates
that this agent kills colon tumor cells primarily by affecting DNA
metabolism, thus demonstrating that 5-FU and FdUrd have very
different mechanisms of action.
Figure 6. PARP inhibition sensitizes MMR-deficient cells to
FdUrd. (A) HT29 cells transfected with control (Luc), MSH2, or MLH1
s R N A sw e r ep l a t e da ss i n g l ec e lls, exposed to the indicated
concentrations of 5-FU or FdUrd for 24 h, washed, cultured for 10 d,
and stained with Coomassie Blue. Transfected cells were also
sequentially immunoblotted for MSH2 or MLH1 and beta-actin (a
loading control). (B) HCT116.ch2 and HCT116.ch3 cells were exposed to
the indicated concentrations of FdUrd along with vehicle or 300 nM
AZD2281 for 24 h. Following washing, AZD2281 was re-added and the
cells were cultured for 8 d to allow colony formation.
doi:10.1371/journal.pone.0028862.g006
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initiated to identify the checkpoint and DNA repair pathways
that regulate colon tumor responses to FdUrd and 5-FU,
demonstrated that BER was a critical repair pathway when these
cells were exposed to FdUrd (but not 5-FU). Based on these
findings, and the fact that PARP inhibitors disrupt BER, we then
discovered that small molecule PARP inhibitors robustly sensitized
MMR-deficient and –proficient colon cancer cells to FdUrd (but
not 5-FU). These findings may be of particular importance in
tumors with defects in MMR, which account for 15–20% of all
colon cancers [39]. Previous studies found that MMR-deficient
cell lines are less sensitive to 5-FU and FdUrd. Consistent with this
result, clinical studies have shown that 5-FU has limited activity
against MMR-deficient colon cancers compared to MMR-
proficient tumors [39]. Given that 1) FdUrd is approved for the
treatment of colon cancer; and 2) there are limited therapeutic
options for these tumors because tumors with defects in MMR are
commonly considered to be unresponsive to 5-FU-based therapies,
our finding that PARP inhibitors robustly sensitize MMR-deficient
cells to FdUrd raises the possibility that therapies that combine
FdUrd with a PARP inhibitor may have activity against these
tumors. Similarly, because PARP inhibitors also sensitize mis-
match proficient tumors to FdUrd, this drug combination may
also be useful in the treatment of these tumors. Further preclinical
and clinical development of this combination is warranted.
Supporting Information
Figure S1 Effects of ATR and ATM disruptions on
sensitivity to gemcitabine and ionizing radiation. (A)
ATR depletion sensitizes to gemcitabine. HT29 cells transfected
with control (Luc) or ATR siRNAs from experiment shown in
Fig. 2B were plated as single cells, exposed to the indicated
concentrations of gemcitabine for 24 h, washed, and cultured for
10 d to allow colony formation. (B) ATM depletions sensitize to
ionizing radiation (IR). HT29 cells transfected with control (Luc)
or ATM siRNAs from experiment shown in Fig. 2A were plated as
single cells, exposed to the indicated doses of ionizing radiation,
and cultured for 10 d to allow colony formation. (C–D) The ATM
inhibitor KU-55933 does not affect the sensitivity of HT-29 cells to
FdUrd but sensitizes to ionizing radiation (IR). HT29 cells were
plated as single cells and allowed to adhere for 4 h. For the FdUrd
experiment (C), the cells were first exposed to the indicated
concentrations of KU-55933 for 15 min and then FdUrd was
added. Cells were then incubated for 24 h, washed, and cultured
for 10 d to allow colony formation. For the IR experiment (D), the
cells were exposed to the indicated concentrations of KU-55933
for 15 min, irradiated, washed after 24 h to remove the KU-
55933, and cultured for 10 d to allow colony formation.
(TIF)
Figure S2 APE1 depletion sensitizes HT29 cells to
FdUrd. Cells were transfected with control (Luc) or APE1
siRNAs. 48 h later, the cells were plated as single cells, treated
with the indicated concentrations of FdUrd for 24 h, washed, and
cultured for 10 d to allow colony formation.
(TIF)
Figure S3 Depletion of MSH2 and MLH1 disrupts
MNNG-induced G2/M cell cycle arrest. HT29 cells
transfected with control (Luc), MSH2, or MLH1 siRNAs were
incubated with 3 mM N-methyl-N9-nitro-N-nitrosoguanidine
(MNNG) for 24 h, stained with propidium iodide and analyzed
by flow cytometry for DNA content.
(TIF)
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